CS
IMNM icon

Candriam SCA’s Immunome IMNM Stock Holding History

Candriam SCA’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.8M Hold
539,882
– – 0.06% 252
2025
Q4 		$11.6M Sell
539,882
-319,645
-37% -$5.61M 0.06% 256
2025
Q3 		$10.1M Buy
859,527
+541,441
+170% +$5.39M 0.05% 276
2025
Q2 		$2.96M Buy
+318,086
New +$2.61M 0.02% 433

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Candriam SCA's IMNM Position: Q1 2026 in Review

Candriam SCA held its Immunome (IMNM) position steady in Q1 2026 at 539,882 shares worth $11.8M. The position accounts for 0.06% of the portfolio, ranked #252.

Candriam SCA first reported a position in IMNM in Q2 2025 and has held it in 4 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Candriam SCA held 539,882 shares of Immunome worth $11.8M as of Q1 2026.
  • Candriam SCA left its Immunome share count unchanged in Q1 2026.
  • Immunome made up 0.06% of Candriam SCA's portfolio in Q1 2026, its #252 holding.
  • Candriam SCA first reported a position in Immunome in Q2 2025 and has held it in 4 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.